Dose-escalation study of G1T48, an oral selective estrogen receptor degrader (SERD), in postmenopausal women with ER+/HER2- locally advanced or metastatic breast cancer (ABC)

MLA

E.G.E. de Vries, et al. “Dose-Escalation Study of G1T48, an Oral Selective Estrogen Receptor Degrader (SERD), in Postmenopausal Women with ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ABC).” Annals of Oncology, vol. 30, Oct. 2019, pp. v121–22. EBSCOhost, https://doi.org/10.1093/annonc/mdz242.035.

APA

E.G.E. de Vries, Jie Xiao, Chao Li, Elizabeth Claire Dees, Houven van Oordt, C.W. Menke-van der, Philippe Aftimos, Andrew P. Beelen, Patrick Neven, Christina Sipes, Mark D. Pegram, Rajesh K. Malik, James E. Boers, Jessica A. Sorrentino, & Ramsha Iqbal. (2019). Dose-escalation study of G1T48, an oral selective estrogen receptor degrader (SERD), in postmenopausal women with ER+/HER2- locally advanced or metastatic breast cancer (ABC). Annals of Oncology, 30, v121–v122. https://doi.org/10.1093/annonc/mdz242.035

Chicago

E.G.E. de Vries, Jie Xiao, Chao Li, Elizabeth Claire Dees, Houven van Oordt, C.W. Menke-van der, Philippe Aftimos, et al. 2019. “Dose-Escalation Study of G1T48, an Oral Selective Estrogen Receptor Degrader (SERD), in Postmenopausal Women with ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ABC).” Annals of Oncology 30 (October): v121–22. doi:10.1093/annonc/mdz242.035.